| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
En-Hui Dai, Shu-Hao Que, Huan Xu, Guo-Qiang Zhong, Zhen Zhang, Xu Liang, Shu-Wei Zhai, Yue-Tong Li, Jing-Jing Wang and Wei Feng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82303672 |
| Zhejiang Provincial Health Commission and Zhejiang Provincial Administration of Traditional Chinese Medicine through the Targeted Project for Medical and Health Research |
2025ZL017 |
| China Primary Health Care Foundation |
ZLMY20240311001ZJ |
|
| Corresponding Author |
Wei Feng, MD, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Gongshu District, Hangzhou 310022, Zhejiang Province, China. fengwei@zjcc.org.cn |
| Key Words |
Esophageal cancer; Liver metastasis; Chemotherapy; Immunotherapy; Local liver-directed therapy |
| Core Tip |
Although chemoimmunotherapy is the standard first-line treatment for metastatic esophageal cancer, its efficacy in the subgroup with liver metastases remains poorly characterized. This study demonstrated that chemoimmunotherapy significantly improved overall survival in this population, with a manageable safety profile. Key prognostic factors were identified, and the addition of local therapy to liver metastases may provide a rational approach to further optimize treatment outcomes. |
| Publish Date |
2026-01-12 10:07 |
| Citation |
Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i1.113440 |
